

RIGLIETTI, ROBERT JOHN

| | | | | |
|------------------------|------------|-----------------------------------|-----------------------------|---------------------------|
| DOB: 07/30/1995 | Age: 25 | Specimen: EN360797X | Collected: 10/14/2020 09:24 | Client #: 90505184 |
| Sex: M | Fasting: Y | Requisition: 0007651 | Received: 10/14/2020 09:26 | CHIA, JOHN K |
| Phone: (631) 793-2551 | | Report Status: FINAL / SEE REPORT | Reported: 10/24/2020 16:39 | I.D. MED |
| Patient ID: 07301995RR | | | | 23430 HAWTHORNE BLVD #200 |
| | | | | TORRANCE, CA 90505 |
| | | | | Phone: (310) 784-5880 |
| | | | | Fax: (310) 325-3117 |

FASTING: YES

▲ COXSACKIE B VIRUS ABS

| Analyte | Value | Reference Range |
|------------------------|--------------|-----------------|
| COXSACKIE B1: | <1:10 | <1:10 |
| COXSACKIE B2: | <1:10 | <1:10 |
| COXSACKIE B3: | <1:10 | <1:10 |
| ▲ COXSACKIE B4: | 1:160 | <1:10 |
| COXSACKIE B5: | <1:10 | <1:10 |
| COXSACKIE B6: | <1:10 | <1:10 |

INTERPRETIVE INFORMATION: Coxsackie B Virus
 Single positive antibody titers of greater than or equal to 1:80 may indicate past or current infection. Sero-conversion or an increase in titers between acute and convalescent sera of at least fourfold is considered strong evidence of current or recent infection.

▲ IMMUNOGLOBULIN G SUBCLASSES PANEL

| Analyte | Value | Reference Range |
|--------------------------------------|--------------|-----------------|
| ▲ IMMUNOGLOBULIN G SUBCLASS 1 | 364 L | 382-929 mg/dL |
| IMMUNOGLOBULIN G SUBCLASS 2 | 428 | 241-700 mg/dL |
| IMMUNOGLOBULIN G SUBCLASS 3 | 46 | 22-178 mg/dL |
| IMMUNOGLOBULIN G SUBCLASS 4 | 16.0 | 4-86 mg/dL |
| IMMUNOGLOBULIN G, SERUM | 959 | 600-1640 mg/dL |

▲ HERPESVIRUS 6 ANTIBODIES (IGG, IGM)

| Analyte | Value | Reference Range |
|---------------------------------|---------------|-----------------|
| ▲ HERPESVIRUS 6 AB (IGG) | 1:80 H | titer |
| HERPESVIRUS 6 AB (IGM) | <1:20 | titer |

INTERPRETATION**PAST INFECTION**

REFERENCE RANGE:

IgG <1:10
 IgM <1:20

Human Herpesvirus 6 (HHV-6) infects T-lymphocytes, and has been identified as an etiologic agent of exanthema subitum. Rises in antibody titers to HHV-6 have been detected during infection with other viruses. In seroepidemiology studies of the prevalence of exposure using serum screening dilutions of 1:10, the detection of IgG antibody in a mid-life population approaches 100%. Due to this high prevalence of HHV-6 antibody, correlations of single IgG titers with specific diseases are of little clinical value.

Evidence of acute infection or reactivation of HHV-6 is demonstrated by a significant rise or seroconversion of IgG and IgM titers.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

ECHOVIRUS ANTIBODIES

| Analyte | Value | Reference Range |
|---------------|-------|-----------------|
| ECHOVIRUS 6: | <1:10 | <1:10 |
| ECHOVIRUS 7: | <1:10 | <1:10 |
| ECHOVIRUS 9: | <1:10 | <1:10 |
| ECHOVIRUS 11: | <1:10 | <1:10 |
| ECHOVIRUS 30: | <1:10 | <1:10 |

INTERPRETIVE INFORMATION: Echovirus Antibodies
 Single positive antibody titers of greater than or equal to 1:80 may indicate past or current infection. Seroconversion or an increase in titers between acute and convalescent sera of at least fourfold is considered strong evidence of current or recent infection.

CREATINE KINASE, TOTAL

| Analyte | Value | Reference Range |
|------------------------|-------|-----------------|
| CREATINE KINASE, TOTAL | 52 | 44-196 U/L |

LYMPHOCYTE SUBSET PANEL 1

| Analyte | Value | Reference Range |
|------------------------|-------|-------------------|
| % CD3 (MATURE T CELLS) | 66 | 57-85 % |
| ABSOLUTE CD3+ CELLS | 1297 | 840-3060 cells/uL |
| % CD4 | 45 | 30-61 % |
| ABSOLUTE CD4+ CELLS | 886 | 490-1740 cells/uL |
| % CD8 | 19 | 12-42 % |
| ABSOLUTE CD8+ CELLS | 368 | 180-1170 cells/uL |
| CD4/CD8 RATIO | 2.40 | 0.86-5.00 |